- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Here is the summary for Hikal Ltd.'s financial update:
**1. Financial Highlights:**
Hikal's Q1 FY26 consolidated revenue hit Rs. 380 Cr, with EBITDA at Rs. 25 Cr (6.5% margin), and a net loss of Rs. 23 Cr. Pharma revenue (Rs. 203 Cr) saw an EBIT loss due to temporary off-take deferment. Crop protection (Rs. 178 Cr) faced margin pressure. FY25 balance sheet shows improved operating cashflow and reduced debt.
**2. Strategic Initiatives & Growth Drivers:**
Pharma's Q1 was impacted by a US FDA OAI-related pause, with supplies expected from Q2. Successful GMP audits by ANVISA/PMDA at Bangalore strengthen global market access. Animal health molecules target FY27 commercialization. Crop protection anticipates H2 FY26 volume recovery and efficiency focus.
**3. Business Developments:**
Hikal is actively addressing US FDA observations, with customer audits completed. Both pharma and crop protection CDMO segments report robust project pipelines. Capabilities are expanding in high-potency/complex chemistry and pharma product registrations continue in regulated markets.
**4. Market Position & Competitive Advantage:**
Successful ANVISA/PMDA audits reinforce Hikal's strong compliance and quality commitment, enhancing its global standing. The company maintains operational efficiency via product mix and cost discipline, crucial in competitive sectors.
**5. Investor Implications:**
Despite a challenging Q1, management remains confident in FY26 guidance. Recovery is projected for Q3-Q4, driven by improved demand visibility and new product commercialization, signaling positive growth potential.